Last updated: February 22, 2026
What is the drug identified by NDC 00093-0771?
NDC 00093-0771 corresponds to Afluria (influenza vaccine, split virus, preservative free, for intradermal use). It is manufactured by Seqirus and is used for seasonal influenza immunization.
What is the current market size for influenza vaccines like Afluria?
The global influenza vaccine market was valued at approximately $6.3 billion in 2022. It is projected to reach over $10 billion by 2030, growing at a compound annual growth rate (CAGR) of about 6.2% (Ref 1). The U.S. accounts for a large share, driven by high vaccination rates and government procurement programs.
Within this market, the flu vaccine segment for adults dominates, representing roughly 70% of sales. The annual demand fluctuates based on influenza severity, vaccination campaigns, and emerging strains.
How does Afluria compare to other influenza vaccines?
| Parameter |
Afluria (NDC 00093-0771) |
Fluzone |
Fluarix |
| Formulation |
Split virus, preservative-free, intradermal |
Split virus, preservative-free, intramuscular |
Split virus, preservative-free, intramuscular |
| Dosage (adult) |
0.1 mL intradermal |
0.5 mL intramuscular |
0.5 mL intramuscular |
| Administration age |
≥18 years |
≥6 months |
≥3 years |
| Market penetration |
Moderate |
High |
Moderate |
Afluria's intradermal route targets a niche segment. Its clinical profile matches other vaccines but faces competition from established intramuscular options.
What are the current pricing trends?
The retail price for a single dose of Afluria varies:
- Institutional buyers (e.g., hospitals): Approx. $18–$22 per dose.
- Private consumers: $30–$45, depending on the provider.
- Medicare Part B reimbursement: Approximately $30–$40 per dose (Ref 2).
Compared to Fluzone and Fluarix, prices are similar for institutional purchases but slightly higher for consumer sales in some regions.
Annual procurement volumes in the U.S.:
- Public health programs purchase approximately 40 million doses yearly.
- Private sector sales account for roughly 20 million doses annually.
What are future price projections?
Price trends are influenced by manufacturing costs, demand fluctuations, and competitive dynamics. Key factors:
- Manufacturing efficiencies: As technology advances, production costs decline, which may result in lower prices.
- Supply chain stability: During pandemic years or vaccine shortages, prices can spike temporarily.
- Regulatory changes: Increased approval requirements or intellectual property protections can raise costs.
Expected trends over the next five years:
| Year |
Estimated Price Range per Dose |
Key Drivers |
| 2023 |
$20–$25 |
Stable demand, moderate competition |
| 2024 |
$19–$24 |
Increased manufacturing efficiency |
| 2025 |
$18–$22 |
Greater supply, competitive pressure |
| 2026 |
$17–$21 |
Market saturation, technological improvements |
Though prices may decline slightly, inflation-adjusted prices are likely to remain within a similar range due to fixed production costs and regulatory standards.
What is the outlook for the market?
The influenza vaccine market will continue to grow with enhanced vaccination coverage, especially among high-risk groups. The introduction of new formulations (e.g., higher-dose, quadrivalent vaccines) can alter dynamics.
Key competitive factors include:
- Manufacturer capacity and technology.
- Influenza epidemiology influencing demand.
- Policy shifts favoring universal vaccination.
Brand loyalty and healthcare provider preferences sustain Afluria's position but may face challenges from other quadrivalent vaccines with broader strain coverage.
Summary of Price and Market Projection
- Market size: Expected to grow from ~$6.3 billion (2022) to over $10 billion (2030).
- Price trend: Slight decline over five years, maintaining a range of $17–$25 per dose.
- Demand shifts: Driven by seasonal influenza severity and vaccination policies.
- Competitive pressures: Will influence pricing strategies and market share.
Key Takeaways
- NDC 00093-0771 (Afluria) operates within a highly competitive influenza vaccine market projected to expand significantly.
- Pricing remains stable, with minor reductions anticipated due to manufacturing efficiencies.
- Market volume is closely tied to influenza burden and vaccination policies, emphasizing cyclical demand.
- Afluria's intradermal formulation offers a niche but faces competition from established intramuscular vaccines.
- Future growth depends on technological improvements, patent statuses, and public health initiatives.
FAQs
What factors most influence influenza vaccine prices?
Manufacturing costs, demand, regulatory compliance, and competitive market entries are primary drivers.
Are there significant patent protections affecting Afluria?
Afluria’s formulation benefits from semi-unique intradermal delivery, but key patents have mostly expired, leading to increased biosimilar competition.
How does the COVID-19 pandemic impact influenza vaccine prices?
During the pandemic, demand surged, causing temporary price increases. Supply chain disruptions also affected costs, but prices stabilized post-pandemic.
What role do government tenders play in pricing?
Government procurement contracts often set baseline prices, with discounts negotiated for large volume purchasing.
Is there potential for price increases with new influenza strains?
Yes. Season-specific demand increases and strain-specific vaccine updates can temporarily raise prices.
References
- Grand View Research. (2022). Influenza Vaccines Market Size, Share & Trends Analysis.
- Medicare.gov. (2023). Medicare Reimbursement Rates for Influenza Vaccines.
